XML 42 R27.htm IDEA: XBRL DOCUMENT v3.21.2
Collaborative Research and Development Agreements (Details)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jan. 01, 2021
Nov. 30, 2014
USD ($)
target
Mar. 31, 2014
USD ($)
target
Jun. 30, 2021
USD ($)
Mar. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Jun. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Jun. 30, 2019
USD ($)
Sep. 30, 2018
USD ($)
Dec. 31, 2017
USD ($)
Jun. 30, 2017
USD ($)
Dec. 31, 2016
USD ($)
Sep. 30, 2016
USD ($)
Jun. 30, 2016
USD ($)
Mar. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Jun. 30, 2015
USD ($)
Jun. 30, 2021
USD ($)
milestone
Jun. 30, 2020
USD ($)
Dec. 31, 2011
USD ($)
Deferred Revenue Arrangement [Line Items]                                            
Collaboration revenue       $ 30,027,000     $ 0                         $ 41,274,000 $ 15,000,000  
GSK | Collaborative Research And Development Agreement                                            
Deferred Revenue Arrangement [Line Items]                                            
Upfront license fee received   $ 2,000,000.0 $ 17,000,000.0                                      
Number of outstanding research and development targets | target   4 3                                      
Milestone payments, contingent upon preclinical and clinical trial events (up to)   $ 18,000,000.0                                        
Milestone payments, contingent upon certain U.S. and European regulatory submissions and approvals (up to)   90,000,000.0                                        
Milestone payments, contingent upon achievement of specified levels of worldwide sales (up to)   $ 165,000,000.0                                        
Agreement term following first commercial sale or expiration of the last to expire patent (in years)   12 years                                        
Number of milestones achieved during period | milestone                                       3    
GSK | Initiated in vivo toxicology studies using good laboratory practices (GLPs) | Anti-PD-1 (JEMPERLI/Dostarlimab)                                            
Deferred Revenue Arrangement [Line Items]                                            
Milestones achieved, amount                                     $ 1,000,000.0      
GSK | Initiated in vivo toxicology studies using good laboratory practices (GLPs) | Anti-TIM-3 (GSK4069889A/Cobolimab)                                            
Deferred Revenue Arrangement [Line Items]                                            
Milestones achieved, amount                                   $ 1,000,000.0        
GSK | Initiated in vivo toxicology studies using good laboratory practices (GLPs) | Anti-LAG-3 (GSK40974386)                                            
Deferred Revenue Arrangement [Line Items]                                            
Milestones achieved, amount                             $ 1,000,000.0              
GSK | IND clearance from the FDA | Anti-PD-1 (JEMPERLI/Dostarlimab)                                            
Deferred Revenue Arrangement [Line Items]                                            
Milestones achieved, amount                                 $ 4,000,000.0          
GSK | IND clearance from the FDA | Anti-TIM-3 (GSK4069889A/Cobolimab)                                            
Deferred Revenue Arrangement [Line Items]                                            
Milestones achieved, amount                               $ 4,000,000.0            
GSK | IND clearance from the FDA | Anti-LAG-3 (GSK40974386)                                            
Deferred Revenue Arrangement [Line Items]                                            
Milestones achieved, amount                         $ 4,000,000.0                  
GSK | Phase 2 clinical trial initiation | Anti-PD-1 (JEMPERLI/Dostarlimab)                                            
Deferred Revenue Arrangement [Line Items]                                            
Milestones achieved, amount                         $ 3,000,000.0                  
GSK | Phase 2 clinical trial initiation | Anti-TIM-3 (GSK4069889A/Cobolimab)                                            
Deferred Revenue Arrangement [Line Items]                                            
Milestones achieved, amount                       $ 3,000,000.0                    
GSK | Phase 2 clinical trial initiation | Anti-LAG-3 (GSK40974386)                                            
Deferred Revenue Arrangement [Line Items]                                            
Milestones achieved, amount                 $ 3,000,000.0                          
GSK | Phase 3 clinical trial initiation - first indication | Anti-PD-1 (JEMPERLI/Dostarlimab)                                            
Deferred Revenue Arrangement [Line Items]                                            
Milestones achieved, amount                     $ 5,000,000.0                 $ 40,000,000.0    
GSK | Phase 3 clinical trial initiation - second indication | Anti-PD-1 (JEMPERLI/Dostarlimab)                                            
Deferred Revenue Arrangement [Line Items]                                            
Milestones achieved, amount                   $ 5,000,000.0                        
GSK | Filing of the first BLA - first indication | Anti-PD-1 (JEMPERLI/Dostarlimab)                                            
Deferred Revenue Arrangement [Line Items]                                            
Milestones achieved, amount               $ 10,000,000.0                            
GSK | Filing of the first MAA - first indication | Anti-PD-1 (JEMPERLI/Dostarlimab)                                            
Deferred Revenue Arrangement [Line Items]                                            
Milestones achieved, amount               $ 5,000,000.0                            
GSK | Filing of the first BLA - second indication | Anti-PD-1 (JEMPERLI/Dostarlimab)                                            
Deferred Revenue Arrangement [Line Items]                                            
Milestones achieved, amount         $ 10,000,000.0                                  
GSK | First BLA approval - first indication | Anti-PD-1 (JEMPERLI/Dostarlimab)                                            
Deferred Revenue Arrangement [Line Items]                                            
Milestones achieved, amount       20,000,000.0                                    
GSK | First MAA approval - first indication | Anti-PD-1 (JEMPERLI/Dostarlimab)                                            
Deferred Revenue Arrangement [Line Items]                                            
Milestones achieved, amount       10,000,000.0                                    
GSK | Amendment | Anti-PD-1 (JEMPERLI/Dostarlimab)                                            
Deferred Revenue Arrangement [Line Items]                                            
Revenue recognition multiple deliverable arrangements upfront fee receivable           $ 60,000,000.0                                
Milestones achieved, amount                                       1,100,000,000    
GSK | Amendment | AnaptysBio-generated Zejula                                            
Deferred Revenue Arrangement [Line Items]                                            
Royalty percent on net sales 1.00%                                          
Collaboration revenue                                       1,300,000    
Celgene Corporation | Collaborative Research And Development Agreement                                            
Deferred Revenue Arrangement [Line Items]                                            
Upfront license fee received                                           $ 6,000,000.0
Collaboration revenue       $ 0     $ 0                         $ 0 $ 0  
Maximum milestone payments per target                                           $ 53,000,000.0
Celgene Corporation | Initiated in vivo toxicology studies using good laboratory practices (GLPs) | Anti-PD-1 (CC-90006)                                            
Deferred Revenue Arrangement [Line Items]                                            
Milestone payment earned                               $ 500,000            
Celgene Corporation | Phase 1 clinical trial initiation | Anti-PD-1 (CC-90006)                                            
Deferred Revenue Arrangement [Line Items]                                            
Milestone payment earned                           $ 1,000,000.0